You are here

FDA Says “No” to New Indication for Ezetimibe (Zetia) and Ezetimibe/Simvastatin (Vytorin)

Agency rejects use in reducing cardiovascular risk in heart disease patients

The FDA has issued a complete response letter regarding supplemental new drug applications for ezetimibe (Zetia) and ezetimibe/simvastatin (Vytorin) for reducing the risk of cardiovascular events (i.e., cardiovascular [CV] death, nonfatal myocardial infarction [MI], nonfatal stroke, hospitalization for unstable angina, or the need for revascularization) in patients with coronary heart disease. The applications were based on results from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Both treatments are marketed by Merck, who didn’t give a reason for the agency’s decision in a published statement.

Ezetimibe and ezetimibe/simvastatin are approved for use along with a healthy diet to reduce elevated low-density lipoprotein (LDL) cholesterol in patients with hyperlipidemia. The effect of ezetimibe on cardiovascular morbidity and mortality has not been determined. Moreover, no incremental benefit of ezetimibe/simvastatin on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.

Ezetimibe, administered alone or in combination with a statin, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol, LDL cholesterol, apolipoprotein B, and non–high-density lipoprotein (HDL) cholesterol in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.

Ezetimibe/simvastatin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B, triglycerides, and non-HDL cholesterol, and to increase HDL cholesterol in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia when diet alone is not enough.

IMPROVE-IT was an international, randomized, double-blind, active-comparator study involving 18,144 high-risk patients with an acute coronary syndrome (ACS), including unstable angina, non–ST-segment elevation acute MI (NSTEMI), and ST-segment elevation acute MI (STEMI). The study assessed the incidence of major CV events, as measured by a composite of CV death, nonfatal MI, nonfatal stroke, rehospitalization for ACS, or coronary revascularization (occurring 30 days or more after the initial event), in patients treated with ezetimibe/simvastatin compared with patients treated with simvastatin alone.

All of the patients were started at doses of ezetimibe/simvastatin 10/40 mg or simvastatin 40 mg. Before a 2011 protocol amendment, the dose could be titrated to ezetimibe/simvastatin 10/80 mg or simvastatin 80 mg if successive LDL-C values exceeded 79 mg/dL. The study enrolled patients within 10 days of ACS hospitalization who had sufficient risk, as defined in the protocol, and who had an initial LDL-C less than or equal to 125 mg/dL if lipid-lowering drug naïve or less than 100 mg/dL if on a prior prescription lipid-lowering therapy identified as no more potent than simvastatin 40 mg/day. The LDL-C entry limitations were designed to enroll patients who were reasonably anticipated to achieve LDL-C levels of 70 mg/dL or less in the simvastatin-only cohort, which was the optional recommended target set in the 2004 update to the Adult Treatment Panel (ATP) III guidelines.

IMPROVE-IT met its primary and all secondary composite efficacy endpoints. At seven years, 33% of patients treated with taking ezetimibe/simvastatin experienced a first primary endpoint event (a major cardiovascular event) compared with 35% of patients receiving simvastatin alone, which corresponded to a 6.4% relative risk reduction and a 2.0% absolute risk reduction (hazard ratio, 0.936; P = 0.016). The mean LDL-C levels at one year were 53 mg/dL in the ezetimibe/simvastatin arm and 70 mg/dL in the simvastatin monotherapy arm.

Sources: Merck; February 15, 2016; and Merck; June 3, 2015.


Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug